Richard Paulson - Oct 15, 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
President and CEO, Director
Signature
/s/ Nancy Smith as Attorney-in-Fact for Richard Paulson
Stock symbol
KPTI
Transactions as of
Oct 15, 2025
Transactions value $
$0
Form type
4
Date filed
10/16/2025, 04:29 PM
Previous filing
Sep 16, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Paulson Richard A. President and CEO, Director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON /s/ Nancy Smith as Attorney-in-Fact for Richard Paulson 2025-10-16 0001804460

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +114K +135.98% $0.00 198K Oct 15, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026.